<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364572</url>
  </required_header>
  <id_info>
    <org_study_id>WU#06-20009A</org_study_id>
    <nct_id>NCT00364572</nct_id>
  </id_info>
  <brief_title>Efficacy of Epidural Etanercept in the Treatment of Sciatica</brief_title>
  <official_title>Efficacy of Epidural Etanercept in the Treatment of Sciatica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor
      for the development of radiculopathy. In animal studies, the application of TNF-alpha to
      nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha
      inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior.
      Open-label studies in humans have shown both etanercept and infliximab provide excellent,
      long-term relief in patients with acute radiculopathy from herniated disc. However, a recent
      placebo-controlled study failed to demonstrate any significant difference from placebo. The
      investigators have already established the safety of neuraxial etanercept in a trial that has
      just been completed (not yet published). The objective of this study is to determine whether
      small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for
      LBP caused by nerve root irritation (i.e., radiculopathy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As per the wishes of the Dept. of the Army and Walter Reed Army Medical Center Dept. of
      Clinical Investigation, patients will be randomized in a 3:1 ratio to receive 2
      transforaminal epidural etanercept or saline injections at 2-week intervals. Both patients
      and physicians will be blinded as to the injectate and treatment group. There will be 3 study
      groups. Group I will receive either 2 mg of etanercept or saline per injection. Group II will
      receive either 4 mg of etanercept or saline per injection. Group III will receive either 6 mg
      of etanercept or saline per injection. In each group there will be 8 patients: 6 who receive
      etanercept and 2 who receive saline. As per a previous study we just completed, etanercept
      doses will not be escalated until all 6 patients have completed their 1-month follow-up
      visits without any evidence of toxicity or complications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale pain score, Oswestry disability index, medication intake</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global perceived effect, white blood cell count</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two injections of epidural saline 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural injection of etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two injections of epidural etanercept 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epidural injection of etanercept</intervention_name>
    <description>2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg</description>
    <arm_group_label>Epidural injection of etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (control procedure)</intervention_name>
    <description>Two injections of epidural saline 2 weeks apart</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic low back pain of radicular origin of &gt; 2 months but &lt; 1 year duration.

          2. Failure of conservative therapy to include physical and pharmacotherapy.

          3. MRI evidence of a herniated disc corresponding to the patient's radicular symptoms.

          4. Normal white blood cell count (drawn in 1 blood vial).

        Exclusion Criteria:

          1. Uncontrolled coagulopathy.

          2. Pregnancy, which will be ruled out by a urine pregnancy test if any question as to the
             patient's status exists.

          3. Allergy to contrast dye.

          4. Unstable medical condition (e.g., unstable angina or congestive heart failure).

          5. Rheumatoid arthritis, Crohn's disease or spondylarthropathy.

          6. Unstable neurological condition (e.g., multiple sclerosis)

          7. Systemic infection

          8. Age &lt; 18 or &gt; 70 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven P Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine and Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ozaktay AC, Cavanaugh JM, Asik I, DeLeo JA, Weinstein JN. Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats. Eur Spine J. 2002 Oct;11(5):467-75. Epub 2002 Jun 4.</citation>
    <PMID>12384756</PMID>
  </results_reference>
  <results_reference>
    <citation>Olmarker K, Larsson K. Tumor necrosis factor alpha and nucleus-pulposus-induced nerve root injury. Spine (Phila Pa 1976). 1998 Dec 1;23(23):2538-44.</citation>
    <PMID>9854752</PMID>
  </results_reference>
  <results_reference>
    <citation>Olmarker K, Nutu M, Størkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine (Phila Pa 1976). 2003 Aug 1;28(15):1635-41; discussion 1642.</citation>
    <PMID>12897484</PMID>
  </results_reference>
  <results_reference>
    <citation>Igarashi T, Kikuchi S, Shubayev V, Myers RR. 2000 Volvo Award winner in basic science studies: Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats. Spine (Phila Pa 1976). 2000 Dec 1;25(23):2975-80.</citation>
    <PMID>11145807</PMID>
  </results_reference>
  <results_reference>
    <citation>Korhonen T, Karppinen J, Malmivaara A, Autio R, Niinimäki J, Paimela L, Kyllönen E, Lindgren KA, Tervonen O, Seitsalo S, Hurri H. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine (Phila Pa 1976). 2004 Oct 1;29(19):2115-9.</citation>
    <PMID>15454701</PMID>
  </results_reference>
  <results_reference>
    <citation>Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Järvinen S, Niinimäki J, Veeger N, Seitsalo S, Hurri H. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine (Phila Pa 1976). 2005 Dec 15;30(24):2724-8.</citation>
    <PMID>16371894</PMID>
  </results_reference>
  <results_reference>
    <citation>Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004 Sep;63(9):1120-3. Epub 2004 Apr 28.</citation>
    <PMID>15115710</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen SP, Griffith S, Larkin TM, Villena F, Larkin R. Presentation, diagnoses, mechanisms of injury, and treatment of soldiers injured in Operation Iraqi Freedom: an epidemiological study conducted at two military pain management centers. Anesth Analg. 2005 Oct;101(4):1098-103, table of contents.</citation>
    <PMID>16192528</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steve P. Cohen</name_title>
    <organization>Walter Reed Army Medical Center</organization>
  </responsible_party>
  <keyword>sciatica</keyword>
  <keyword>low back pain</keyword>
  <keyword>epidural</keyword>
  <keyword>tumor necrosis factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

